Economic evaluation of isosorbide mononitrate sustained-release capsules for the treatment of angina pectoris

Objective

Systematically evaluate the efficacy of (1) isosorbide mononitrate sustained-release capsules combined with conventional therapy and (2) conventional therapy alone in the treatment of angina pectoris and analyze their economic value to provide evidence and a reference for clinical medication and decision-making.

Methods

Randomized controlled trials on the efficacy of isosorbide mononitrate sustained-release capsules combined with conventional therapy and conventional therapy in the treatment of angina pectoris were searched and abstracted from major Chinese and English literature databases from August 26, 2003 to August 26, 2023, to calculate the rate of improvement in clinical symptoms using isosorbide mononitrate sustained-release capsules combined with conventional therapy (observation group) and using conventional therapy alone (control group). Review Manager 5.4 software was used for meta-analysis, and an economic evaluation was performed using cost-effectiveness analysis (CEA).

Results

The effectiveness rates for clinical symptom improvement were 95% in the observation group and 78% in the control group. According to the meta-analysis results, the efficiency of clinical symptom improvement in the observation group, which received the combination therapy with isosorbide mononitrate sustained-release capsules, was significantly better than that of the control group (OR ​= ​3.38, 95% CI: 2.28 to 4.99, P ​< ​0.001). The CEA indicated an incremental cost-effectiveness ratio of 434.12 yuan, and the sensitivity analysis results demonstrated that the evaluation outcomes were stable, suggesting a robust foundation for the study's conclusions.

Conclusions

Compared with conventional therapy alone, isosorbide mononitrate sustained-release capsules combined with traditional treatment have good efficacy and safety in the treatment of angina pectoris and have certain economic advantages.